Cancer

Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as HNF4α, CADM2, p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 18/October/2018, 5.18 am
Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as HNF4α, CADM2, p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 18/October/2018, 5.18 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 16/October/2018, 1.38 pm
Taming cancers with anti-tapeworm drugs: Niclosamide (brand name: Niclocide, Fenasal, Phenasal), an anti-tapeworm drug,  increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human cancers and other cancers, via up-regulation of its target gene, 16/October/2018, 1.38 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Niclosamide, Curcumin, Chlorpromazine, Procainamide, IP-504, and Salinomycin inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/October/2018, 12.42 pm
Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Niclosamide, Curcumin, Chlorpromazine, Procainamide, IP-504, and Salinomycin inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/October/2018, 12.42 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 16/October/2018,12.17 pm
Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 16/October/2018,12.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more

Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 13/October/2018, 10.49 am
Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 13/October/2018, 10.49 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Molecular therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/October/2018,10.26 am
Molecular therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/October/2018,10.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more
Start Typing